Ten-year experience with arterial embolization for peptic ulcer bleeding: N-butyl cyanoacrylate glue versus other embolic agents

Affiliation auteurs!!!! Error affiliation !!!!
TitreTen-year experience with arterial embolization for peptic ulcer bleeding: N-butyl cyanoacrylate glue versus other embolic agents
Type de publicationJournal Article
Year of Publication2021
AuteursLoffroy R, Desmyttere A-S, Mouillot T, Pellegrinelli J, Facy O, Drouilllard A, Falvo N, Charles P-E, Bardou M, Midulla M, Aho-Glegle S, Chevallier O
JournalEUROPEAN RADIOLOGY
Volume31
Pagination3015-3026
Date PublishedMAY
Type of ArticleArticle
ISSN0938-7994
Mots-clésCyanoacrylates, Glubran 2, humans, Peptic ulcer hemorrhage, retrospective studies
Résumé

{Objectives To compare our experience with N-butyl cyanoacrylate glue as the primary embolic agent versus other embolic agents for transcatheter arterial embolization (TAE) in refractory peptic ulcer bleeding and to identify factors associated with early rebleeding and 30-day mortality. Methods Retrospective study of 148 consecutive patients comparing the clinical success rate in 78 patients managed with Glubran (R) 2 N-butyl cyanoacrylate metacryloxysulfolane (NBCA-MS) alone or with other agents and 70 with other embolic agents only (coils, microspheres, ethylene-vinyl alcohol copolymer, or gelatin sponge) at a university center in 2008-2019. Univariate and multivariate logistic regression analyses were done to identify prognostic factors. Results The technical success rate was 95.3% and the primary clinical success was 64.5%. The early rebleeding and day-30 mortality rates were 35.4% and 21.3%, respectively. Rebleeding was significantly less common with than without Glubran (R) 2 (OR, 0.47; 95% CI, 0.22-0.99; p = .047) and significantly more common with coils used alone (OR, 20.4; 95% CI, 10.13-50.14; p = .024). The only other factor independently associated with early rebleeding was having two or more comorbidities (OR, 20.14; 95% CI, 10.01-40.52; p = .047). Day-30 mortality was similar in the two treatment groups. A lower initial hemoglobin level was significantly associated with higher day-30 mortality (OR, 10.38; 95% CI, 10.10-10.74; p = .006). Fluoroscopy time was significantly shorter with Glubran (R) 2 (20.8 +/- 11.5 min vs. 35.5 +/- 23.4 min

DOI10.1007/s00330-020-07427-y